Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Twilio Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Twilio Inc trades at $255 (market cap $38.40B). The key difference: Twilio Inc is far larger — about 4.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | TWLO | |
|---|---|---|
Market Cap | $9.39B | $38.40B |
Sector | Health | Technology |
52-Week High | $356.25 | $255.95 |
52-Week Low | $241.71 | $95.23 |
Enterprise Value | $9.14B | $36.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Twilio (TWLO) trades at $241.28, up 24.89% in 24 hours, near its 52-week high. The stock is in a bullish technical trend with strong support at $228 and resistance at $255. Recent Q2 2026 earnings beat expectations with EPS of $1.47 versus $1.32 expected, and revenue grew 22% year-over-year to $1.5 billion. The company raised full-year 2026 revenue growth guidance to 18%-18.5%.
The outlook is positive with accelerating revenue growth and improving profitability, but risks include high valuation multiples and reliance on continued execution. Analyst consensus is strongly bullish with a $266.31 price target, though the stock's rapid ascent warrants caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
